Category: Latest News
-
BullFrog AI lands first pharma deal, expands AI drug discovery push
BullFrog AI Holdings Inc (NASDAQ:BFRG) said it has secured its first commercial agreement with a major global pharmaceutical company, marking a key milestone as it enters the second quarter of 2026 with a strengthened financial position. The deal, announced on March 30, will see BullFrog deploy its bfLEAP® platform to identify potential drug targets for…
-
Rectitude wins over S$10m in green energy system orders
Rectitude Holdings Ltd (NASDAQ:RECT) said it has secured more than S$10 million in rental and sales orders for its All-in-One Intelligence Micro-Grid System (AIMS) during the second half of fiscal 2026. The update comes as the stock trades close to its 52-week low of $1.00, having fallen about 70% over the past year to around…
-
RedCloud secures $30M Saudi licensing deal for RAID AI platform
RedCloud Holdings plc (NASDAQ:RCT) has signed a five-year licensing agreement worth up to $30 million to deploy its RAID AI engine in Saudi Arabia’s fast-moving consumer goods (FMCG) sector. The contract is structured to generate $6 million annually, tied to revenues produced by RAID within the Saudi market. The deal targets the Kingdom’s FMCG sector,…
-
T-Mobile gains after KeyBanc upgrade highlights growth outlook
T-Mobile US Inc (NASDAQ:TMUS) shares edged higher on Monday after KeyBanc Capital Markets upgraded the stock, pointing to sustained business momentum and strong future prospects. KeyBanc lifted its rating on the telecom group to “Overweight,” citing solid growth potential, improving profitability, and an attractive valuation relative to peers. The firm set a price target of…
-
Northrop Grumman moves Sentinel missile program closer to 2027 first flight
Northrop Grumman Corporation (NYSE:NOC) and the U.S. Air Force reported continued progress on the Sentinel intercontinental ballistic missile program, with a first flight targeted for 2027 and initial operational capability expected in the early 2030s. The LGM-35A Sentinel system is being developed to replace the aging Minuteman III ground-based nuclear deterrent across a footprint spanning…
-
REPAY defends KUBRA deal following Veradace letter
Repay Holdings Corporation (NASDAQ:RPAY) has responded to a letter from Veradace Partners addressing governance concerns and the company’s proposed acquisition of KUBRA. The board confirmed it has reviewed Veradace’s correspondence and reiterated its support for the KUBRA transaction, arguing that the deal will expand REPAY’s presence in bill payment services, strengthen its role in payment…
-
GoPro teams up with Oliver Wyman to target defense and aerospace opportunities
GoPro (NASDAQ:GPRO) said it is expanding into the defense and aerospace sectors, partnering with consulting firm Oliver Wyman to assess potential applications for its camera technology. The San Mateo-based company said the collaboration will focus on identifying addressable markets, evaluating technology fit, and developing go-to-market strategies for government and defense use cases. The initiative will…
-
Revolution Medicines shares jump on breakthrough pancreatic cancer trial results
Revolution Medicines (NASDAQ:RVMD) surged 33% on Monday after announcing positive topline findings from its Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma patients. The study achieved all primary and key secondary endpoints, including both progression-free survival and overall survival. Daraxonrasib delivered a median overall survival of 13.2 months, compared…
-
HPE shares fall as analysts flag slower growth outlook
Hewlett Packard Enterprise (NYSE:HPE) shares dropped more than 3% on Monday after analysts raised concerns about the company’s near-term growth trajectory. Raymond James downgraded the stock from “Strong Buy” to “Outperform,” citing softer growth expectations while maintaining a constructive long-term view. The firm said the move reflects “less certainty around growth and catalysts,” even as…
-
Eli Lilly reports positive Phase 3 results for Jaypirca in blood cancer study
Eli Lilly and Company (NYSE:LLY) said its therapy Jaypirca achieved the primary endpoint in a Phase 3 trial involving patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The BRUIN CLL-322 study evaluated Jaypirca in combination with venetoclax and rituximab against a regimen of venetoclax and rituximab alone in 639 patients…